Free Trial
NASDAQ:ACHL

Achilles Therapeutics (ACHL) Stock Price, News & Analysis

Achilles Therapeutics logo
$1.48 0.00 (0.00%)
As of 03/26/2025

About Achilles Therapeutics Stock (NASDAQ:ACHL)

Key Stats

Today's Range
$1.48
$1.48
50-Day Range
$1.37
$1.49
52-Week Range
$0.63
$1.51
Volume
N/A
Average Volume
575,481 shs
Market Capitalization
$60.83 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Achilles Therapeutics plc, a biopharmaceutical company, develops precision T cell therapies to treat solid tumors. Its platform identifies mutations formed early in the development of cancer. The company offers PELEUS, a proprietary AI-powered bioinformatics platform, used to identify clonal neoantigens in a patient. It also develops CHIRON, which is in Phase I/IIa clinical trial for use in the treatment of advanced non-small cell lung cancer; and THETIS, a product candidate in Phase I/IIa clinical trial for use in the treatment of metastatic or recurrent melanoma. The company was formerly known as Achilles TX Limited and changed its name to Achilles Therapeutics Plc in February 2021. Achilles Therapeutics Plc was founded in 2016 and is headquartered in London, the United Kingdom.

Receive ACHL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Achilles Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

ACHL Stock News Headlines

Here’s How to Claim Your Stake in Elon’s Private Company, xAI
I predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new millionaires than any tech advance in history. And for a limited time, you have the chance to claim a stake in this project, even though it’s housed inside Elon’s private company, xAI.
See More Headlines

ACHL Stock Analysis - Frequently Asked Questions

Achilles Therapeutics' stock was trading at $1.14 on January 1st, 2025. Since then, ACHL stock has increased by 29.8% and is now trading at $1.48.
View the best growth stocks for 2025 here
.

Achilles Therapeutics plc (NASDAQ:ACHL) issued its quarterly earnings data on Wednesday, August, 14th. The company reported ($0.41) EPS for the quarter, hitting analysts' consensus estimates of ($0.41).

Achilles Therapeutics (ACHL) raised $176 million in an IPO on Wednesday, March 31st 2021. The company issued 9,800,000 shares at $17.00-$19.00 per share. JPMorgan, BofA Securities, Piper Sandler, Chardan, Oppenheimer & Co. and Kempen & Co. served as the underwriters for the IPO.

Shares of ACHL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Achilles Therapeutics investors own include Digital Turbine (APPS), Aquestive Therapeutics (AQST), CRISPR Therapeutics (CRSP), ChargePoint (CHPT) and NVIDIA (NVDA).

Company Calendar

Last Earnings
8/14/2024
Today
5/01/2025
Next Earnings (Estimated)
5/06/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:ACHL
Fax
N/A
Employees
250
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-69,670,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Book Value
$3.49 per share
Price / Book
0.42

Miscellaneous

Free Float
38,889,000
Market Cap
$60.83 million
Optionable
Not Optionable
Beta
1.25
A Beginner's Guide to Investing in Cannabis Cover

Unlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.

Get This Free Report

This page (NASDAQ:ACHL) was last updated on 5/1/2025 by MarketBeat.com Staff
From Our Partners